| abstract |
The present invention relates to a compound of formula (I) which is an inhibitor of complement factor D, wherein R 12 or R 13 in group A is aryl, heteroaryl or heterocycle (R 32 ), or a pharmaceutically acceptable salt or composition thereof; It relates to methods of use and methods of manufacture. The inhibitors described herein target factor D and inhibit or modulate the complement cascade at early and critical points in other complement pathways, and reduce the ability of factor D to modulate the classical lectin complement pathway. Inhibitors of factor D described herein can reduce excessive activation of complement, which has been associated with certain autoimmune, inflammatory and neurodegenerative diseases, as well as ischemic reperfusion injury and cancer. |